Multiple physical complaints (score 0 if GI symptoms only)
Loss of interest — less involved in usual activities
Physical Signs
Appetite loss — eating less than usual
Weight loss (2 lbs or more in 1 month)
Lack of energy — fatigues easily, unable to sustain activities
Cyclic Functions
Diurnal variation of mood — symptoms worse in the morning
Difficulty falling asleep
Multiple awakenings during sleep
Early morning awakening — earlier than usual
Ideational Disturbance
Suicidal ideation — feels life is not worth living, has suicidal wishes, or makes attempt
Poor self-esteem — self-blame, self-depreciation, feelings of failure
Pessimism — anticipation of the worst
Mood-congruent delusions — delusions of poverty, illness, or loss
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Detecting depression in patients with mild to severe dementia where self-report scales are unreliable.
Distinguishing depressive pseudodementia from primary dementia.
Monitoring antidepressant treatment response in dementia patients.
Routine assessment in memory clinics and dementia care units.
Why Not GDS-15 in Dementia?
The GDS-15 and PHQ-9 rely entirely on patient self-report. In moderate-to-severe dementia, patients cannot reliably introspect or remember their mood states. The CSDD uses structured informant interview combined with direct patient observation to overcome this limitation.
Section 2
Formula & Logic
Scoring
19 items across 5 domains
Each item: 0 (absent), 1 (mild/intermittent), 2 (severe)
Total score: 0–38
Score > 10: Probable major depression
Score 8–10: Mild/possible depression
Score < 8: No significant depression
5 Assessed Domains
Mood-Related Signs
Anxiety, sadness, lack of reactivity to pleasant events, irritability
Behavioural Disturbance
Agitation, retardation, multiple complaints, loss of interest, inability to feel pleasure
Do not administer the CSDD during an episode of delirium. Agitation, sleep disturbance, and poor appetite from delirium can falsely elevate the score. Reassess 1–2 weeks after delirium resolution.
Section 4
Next Steps
Management by Score
< 8 (No depression)
Reassure. Repeat at next clinical review or if clinical concern.
8–10 (Mild/possible)
Non-pharmacological interventions: structured activity, social engagement, carer support.
> 10 (Probable major depression)
Antidepressant trial (SSRI preferred in dementia). Psychiatry input. Exclude vascular depression or BPSD.
Section 5
Evidence Appraisal
Primary Reference
Cornell Scale for Depression in Dementia.
Alexopoulos GS et al. • Biol Psychiatry.. 1988;23(3):271–284. Derivation and validation in 107 patients; interrater reliability ICC 0.67 (patient interview) and 0.83 (informant interview).
Section 6
Origins
George Alexopoulos — Weill Cornell Medical College
Developed by George Alexopoulos at Weill Cornell Medical College in 1988. The CSDD was created to fill the diagnostic void for depression assessment in dementia patients — a population excluded from or performing unreliably on existing depression rating scales. It remains the reference standard for depression screening in dementia research and clinical practice.
